MAINTENANCE OF LEBRIKIZUMAB EFFICACY IN MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS WITH STABLE ASTHMA CONTROL

被引：0
|
作者：
Mehta, V.
Worm, M.
Chiesa, Z.
Natalie, C.
Dawson, Z.
Zhong, J.
Diemert, S.
Boguniewicz, M.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2023年 / 131卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P280
引用
收藏
页码：S89 / S90
页数：2
相关论文
共 50 条
  • [21] Lebrikizumab demonstrates significant efficacy versus placebo across racial and ethnic subgroups in patients with moderate-to-severe atopic dermatitis
    Alexis, Andrew
    Ardern-Jones, Michael
    Chovatiya, Raj
    Flohr, Carsten
    Irvine, Alan
    AlMurrawi, Muna
    Atwater, Amber Reck
    Ding, Yuxin
    Qiao, Meihua
    Pierce, Evangeline
    Pau-Charles, Ignasi
    Heath, Candrice
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II20 - II21
  • [22] Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Eichenfield, L. F.
    Blauvelt, A.
    Rosmarin, D.
    Hussain, I.
    Davis, J. D.
    Li, M.
    Zhang, Q.
    Gadkari, A.
    Eckert, L.
    Kamal, M. A.
    Bansal, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S104 - S104
  • [23] Efficacy and tolerance of dupilumab in patients with moderate-to-severe atopic dermatitis and obesity
    Dupuis, Josephine
    Tauber, Marie
    Mahe, Emmanuel
    Jachiet, Marie
    Soria, Angele
    Tetart, Florence
    Puzenat, Eve
    Pasteur, Justine
    Raison-Peyron, Nadia
    Giordano-Labadie, Francoise
    Droitcourt, Catherine
    Leleu, Camille
    Nosbaum, Audrey
    Aubert, Helene
    Moigne, Marie L. E.
    Bernier, Claire
    Barbarot, Sebastien
    Ezzedine, Khaled
    Diaz, Emmanuelle
    Hubiche, Thomas
    Faiz, Sarah
    Azib, Selma
    Dezoteux, Frederic
    Chosidow, Olivier
    Staumont-Salle, Delphine
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025, 39 (02) : e174 - e178
  • [24] Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy
    Silverberg, Jonathan I.
    Bieber, Thomas
    Paller, Amy S.
    Beck, Lisa
    Kamata, Masahiro
    Puig, Luis
    Wiseman, Marni
    Ezzedine, Khaled
    Irvine, Alan D.
    Foley, Peter
    Del Rosso, James
    Gold, Linda Stein
    Johansson, Erin
    Dossenbach, Martin
    Gallo, Gaia
    Akmaz, Buelent
    Casillas, Marta
    Karlsson, Andrei
    Curteis, Tristan
    Chovatiya, Raj
    DERMATOLOGY AND THERAPY, 2025, 15 (03) : 615 - 633
  • [25] The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
    Bashrahil, Bader
    Alzahrani, Ziyad
    Samarkandy, Sahal
    Aman, Abdullah
    Jfri, Abdulhadi
    FRONTIERS IN MEDICINE, 2023, 9
  • [26] LEBRIKIZUMAB MONOTHERAPY REDUCES FLARES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
    Del Rosso, James Q.
    Kwong, Pearl
    Hussain, Iftikhar
    Barbarot, Sebastien
    Manuel Carrascosa, Jose
    Rueda, Maria Jose
    Atwater, Amber Reck
    Elmaraghy, Hany
    Sun, Luna
    Chen, Sherry
    Natalie, Chitra R.
    Weidinger, Stephan
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 32 - 32
  • [27] Efficacy comparison of targeted systemic monotherapies including lebrikizumab for moderate-to-severe atopic dermatitis: a network meta-analysis
    Silverberg, Jonathan, I
    Bieber, Thomas
    Paller, Amy
    Beck, Lisa A.
    Kamata, Masahiro
    Puig, Luis
    Wiseman, Marni
    Ezzedine, Khaled
    Foley, Peter
    Johansson, Erin
    Dossenbach, Martin
    Akmaz, Bulent
    Casillas, Marta
    Karlsson, Andrei
    Chovatiya, Raj
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 15 - 16
  • [28] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies
    Schmid-Grendelmeier, Peter
    Gooderham, Melinda J.
    Hartmann, Karin
    Konstantinou, George N.
    Fellmann, Marc
    Koulias, Christopher
    Clibborn, Claire
    Biswas, Pinaki
    Brunner, Patrick M.
    ALLERGY, 2024, 79 (01) : 174 - 183
  • [29] Lebrikizumab: a new anti-IL-13 agent for treating moderate-to-severe atopic dermatitis
    Stingeni, Luca
    Ferrucci, Silvia
    Amerio, Paolo
    Foti, Caterina
    Patruno, Cataldo
    Girolomoni, Giampiero
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (01) : 15 - 20
  • [30] Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply
    Guttman-Yassky, Emma
    Simpson, Eric L.
    Reich, Kristian
    Kabashima, Kenji
    Igawa, Ken
    Suzuki, Tetsuya
    Mano, Hirotaka
    Matsui, Takeshi
    Esfandiari, Ehsanollah
    Furue, Masutaka
    LANCET, 2023, 402 (10415): : 1834 - 1834
12345